EMCDDA Home
  • EN
Search

Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances

EMCDDA, Lisbon, May 2014

Publication type:

Risk assessments

Issue:

12

Summary:

This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this hallucinogenic drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as pdf (324Kb):

English (en)

Table of contents

  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on 25I-NBOMe: a summary
  • Risk Assessment Report of a new psychoactive substance: 25I-NBOMe
  • Annex 1: Technical report on 25I-NBOMe
  • Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
  • Participants of the risk assessment meeting

Pages:

23

Price:

free

ISBN/ISSN:

978-92-9168-748-0

DOI:

10.2810/5725

Catalogue number:

TDAK14001ENN

Page last updated: Wednesday, 08 October 2014